Improvement seen compared with chemotherapy alone for first-line treatment of advanced non-small cell lung cancer<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, May 10, 2023 (HealthDay News) — Cemiplimab plus chemotherapy results in significant overall improvement in pain symptoms and delayed deterioration in cancer-related and lung cancer-specific symptoms and functions, according to a study published online May 8 in Cancer<\/em>.<\/p>\n Tamta Makharadze, M.D., from LTD High Technology Hospital Med Center in Batumi, Georgia, and colleagues evaluated patient-reported outcomes from the EMPOWER-Lung 3 phase 3 trial. The analysis included 312 patients assigned to cemiplimab plus platinum-doublet chemotherapy and 154 receiving placebo plus chemotherapy as first-line treatment for advanced non-small cell lung cancer.<\/p>\n The researchers found that for pain symptoms, there was a statistically significant overall improvement from baseline and significant delay in time to definitive clinically meaningful deterioration (TTD; hazard ratio, 0.39; 95 percent confidence interval, 0.26 to 0.60; P < 0.0001) favoring cemiplimab plus chemotherapy. For functioning and symptom scales, there were also statistically significant delays seen in TTD, all favoring cemiplimab plus chemotherapy. From baseline, there was a significant overall improvement observed in global health status\/quality of life with cemiplimab plus chemotherapy versus a nonsignificant overall change from baseline for placebo plus chemotherapy (hazard ratios [95 percent confidence intervals], 1.69 [0.20 to 3.19] versus 1.08 [\u00e2\u0088\u00921.34 to 3.51]; between arms, P = 0.673). <\/p>\n “We show that the favorable efficacy achieved with cemiplimab plus chemotherapy over placebo plus chemotherapy is accompanied by significant overall improvement in pain and significant delay in TTD in multiple patient-reported cancer-related and lung cancer-specific functions and symptoms,” the authors write.<\/p>\n Several authors disclosed financial ties to Regeneron, which manufactures cemiplimab and funded the study.<\/p>\n